Clinical Trials Logo

Polymyositis clinical trials

View clinical trials related to Polymyositis.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03981744 Terminated - Dermatomyositis Clinical Trials

A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments

Start date: July 26, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of ustekinumab in participants with active polymyositis (PM)/dermatomyositis (DM) despite receiving 1 or more standard-of-care treatments (for example, glucocorticoids and/or immunomodulators).

NCT ID: NCT03092154 Terminated - Clinical trials for Treatment Side Effects

Lipid-lowering Agents in Patients With Dermatomyositis and Polymyositis

Start date: January 2017
Phase: N/A
Study type: Interventional

The use of lipid lowering agents in patients with idiopathic inflammatory myopathies is controversial. Therefore, the aim of the present study is to assess clinically and laboratory the impact of lipid-lowering agents in this population.

NCT ID: NCT01801917 Terminated - Polymyositis Clinical Trials

Efficacy and Tolerability of BAF312 in Patients With Polymyositis

Start date: April 24, 2013
Phase: Phase 2
Study type: Interventional

This study assessed the efficacy, safety and tolerability of BAF312 administered orally in patients with clinically active polymyositis and also in patients with polymyositis who had shown inadequate response to corticosteroids and or DMARDs (disease modifying antirheumatic drugs).

NCT ID: NCT01148810 Terminated - Dermatomyositis Clinical Trials

Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis

Start date: June 15, 2010
Phase: Phase 2
Study type: Interventional

This study determined the efficacy, safety, tolerability and the PK profile of BAF312, a novel immunomodulator, in polymyositis and dermatomyositis patients who were not responsive to traditional immunosuppressive and/or corticosteroid therapy. The study consisted of a 12 week, randomized, placebo controlled period, followed by another 12 weeks where all subjects received BAF312 treatment.